Bright Minds Biosciences (TSE:DRUG) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Bright Minds Biosciences is set to present groundbreaking data on its novel drug BMB-101 at the American Epilepsy Society’s 2024 Annual Meeting. The company focuses on innovative treatments for drug-resistant epilepsy and other CNS disorders, showcasing the potential of BMB-101 in advancing epilepsy management.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.
